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Abstract
Background: The U.S. Food and Drug Administration can set standards for cigarettes that could include reducing
their nicotine content. Such a standard should improve public health without causing unintended serious
consequences for sub-populations. This study evaluates the effect of progressive nicotine reduction in cigarettes on
smoking behavior, toxicant exposure, and psychiatric symptoms in smokers with comorbid mood and/or anxiety
disorders using a two-site, two-arm, double-blind, parallel group, randomized controlled trial (RCT) in four phases
over 34 weeks.
Methods: Adult smokers (N = 200) of 5 or more cigarettes per day will be randomized across two sites (Penn State
and Massachusetts General). Participants must have not had a quit attempt in the prior month, nor be planning to
quit in the next 6 months, meet criteria for a current or lifetime unipolar mood and/or anxiety disorder based on
the structured Mini-International Neuropsychiatric Interview, and must not have an unstable medical or psychiatric
condition. After a week of smoking their own cigarettes, participants receive two weeks of Spectrum research
cigarettes with usual nicotine content (11.6 mg). After this baseline period, participants will be randomly assigned
to continue smoking Spectrum research cigarettes that contain either (a) Usual Nicotine Content (11.6 mg); or (b)
Reduced Nicotine Content: the nicotine content per cigarette is progressively reduced from approximately 11.6 mg
to 0.2 mg in five steps over 18 weeks. At the end of the randomization phase, participants will be offered the
choice to either (a) quit smoking with assistance, (b) continue smoking free research cigarettes, or (c) return to
purchasing their own cigarettes, for the final 12 weeks of the study. The primary outcome measure is blood cotinine;
key secondary outcomes are: exhaled carbon monoxide, urinary total NNAL- 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanol and 1-hydroxypyrene, oxidative stress biomarkers including 8-isoprostanes, measures of psychiatric symptoms
(e.g., depression, anxiety), smoking behavior and dependence (e.g., cigarette consumption, quit attempts), and health
effects (e.g., blood pressure, respiratory symptoms).
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Discussion: Results from this study will inform FDA on the potential effects of regulating the nicotine content of
cigarettes and help determine whether smokers with mood and/or anxiety disorders can safely transition to
significantly reduced nicotine content cigarettes.
Trial registration: TRN: NCT01928758, registered August 21, 2013.
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Background
Tobacco smoking is the leading preventable cause of
premature morbidity and mortality in the U.S., [1] and
cessation proffers immediate and sustained improvement
in health and quality of life [2]. The Family Smoking
Prevention and Tobacco Control Act [3] gave the U.S.
Food and Drug Administration (FDA) jurisdiction to
regulate tobacco products, including the nicotine con-
tent of cigarettes. Progressive reduction of the nicotine
content of cigarettes to very low levels is a potential way
to reduce the addictiveness of cigarettes, and may make
it easier for established smokers to quit smoking [4–6].
Preliminary studies have found that progressive reduction
of nicotine content of cigarettes is feasible and safe in
smokers without comorbid psychiatric illness [5, 7–10].
However, it is not known whether progressive nicotine
reduction is feasible and safe in the large subgroup of
smokers with comorbid psychiatric illness.
Smokers with psychiatric illnesses purchase over 40%
of cigarettes sold in the U.S., [11] have a higher preva-
lence of smoking, greater severity of nicotine depend-
ence and lower cessation rates than smokers without
comorbid psychiatric illness [12, 13]. Smokers with a
prior mood or anxiety disorder report more severe nico-
tine withdrawal symptoms during a cessation attempt
[14, 15]. This suggests that a policy to reduce nicotine
content in cigarettes may differentially impact smokers
with affective disorders such that they may have more
severe nicotine withdrawal symptoms and, as a result,
may smoke a greater number of low nicotine cigarettes in
order to reduce withdrawal symptoms, thereby increasing
their exposure to other toxicants in tobacco smoke, a
process termed compensatory smoking [16, 17]. On the
other hand, smokers who transition to significantly re-
duced nicotine content cigarettes may be more likely to
quit smoking due to a lower level of nicotine dependence.
This study aims to test both these hypotheses.
The impact of reduced nicotine cigarettes on smoking
behavior, toxicant exposure and cessation needs to be
assessed empirically prior to implementation of a national
nicotine reduction policy [4, 18]. Early studies of the behav-
ioral effects of a progressive nicotine reduction strategy
have been encouraging. A series of studies by Benowitz and
colleagues examined the effects of a progressive nicotine
reduction strategy in which smokers switched to cigarettes
with progressively lower nicotine content (or yield) in 6
steps, over 10 weeks or over 6 months [7–9]. In their initial
study of 12 smokers, reduced nicotine content (RNC) ciga-
rettes were found to be a feasible option for reducing nico-
tine addiction [9]. In a subsequent study, 20 smokers
consumed gradually reduced nicotine content cigarettes
which did not increase apparent exposure to tobacco
smoke toxins [7]. In a follow up study, 135 otherwise
healthy smokers were randomly assigned to one of two
groups: (a) an experimental group that smoked their usual
brand for two weeks followed by research cigarettes with
five levels of progressively reduced nicotine content (first
four levels for 4 weeks each and the fifth level for 6 months),
or (b) a control group that continued smoking their own
brand of cigarettes for the entire study period [8]. In the
smokers assigned to RNC cigarettes, nicotine intake, as
assessed by plasma cotinine concentration, declined pro-
gressively as the nicotine content of the cigarettes was re-
duced, while toxin exposure remained stable or, in the case
of the carcinogen, (4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanol) (NNAL), was reduced [8]. The titration was well
tolerated, but smokers assigned to the RNC group reported
decreased “vigor” scores and increased “confusion” scores
on the Profile of Mood States (POMS) during the time they
were smoking 2 mg and 1 mg nicotine content cigarettes
(compared with baseline), and smokers assigned to the
RNC group who were adherent to study procedures also
had a 2 kg increase in body weight during the study period
[8]. These effects are consistent with nicotine withdrawal
symptoms [19]. Significantly more of the RNC group (51%)
than the control group (14%), were interested in quitting
smoking by the end of the tapering period. In a recent
study, Donny and colleagues [10] conducted a 6-week,
double-blind, multi-site, parallel, randomized controlled
trial among 840 smokers who were either assigned to
smoke (1) their usual brand cigarettes (study cigarettes), (2)
investigational cigarettes with nicotine content similar to
commercial products (primary control cigarettes), or (3)
one of five investigational cigarettes with 2 to 33% of the
nicotine in the primary control cigarettes. Overall, partici-
pants assigned to the lowest nicotine content cigarettes
significantly reduced the number of cigarettes smoked per
day, which resulted in minimal compensation, reduced
nicotine exposure and dependence, and were more likely to
report quit attempts after a 30-day period following the six-
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week trial compared to those assigned to the primary con-
trol cigarettes [10]. These studies among others [5, 20, 21]
demonstrate that a progressive nicotine reduction strategy
is feasible, results in reduced nicotine exposure, increases
desire to quit smoking and does not result in increased
exposure to other toxicants.
These studies have been well conducted, clear in
their conclusions and represent a critical first step in
the process of empirically evaluating the effects,
intended or unintended, of a policy of progressive
nicotine reduction in cigarettes. However, there are
some issues regarding generalizability of the results
that must be evaluated prior to implementation of
such a policy. A large proportion (>40%) of cigarettes
sold in the United States are sold to those with a
current psychiatric illness, and smoking prevalence is
demonstrably higher among those groups [11]. How-
ever, enrollment in the studies conducted to date has
focused on relatively well-educated, otherwise healthy
smokers. In one study, 35% of those screened were
excluded for current drug or alcohol dependence and
20% for other health issues, and those enrolled had an
average of 15 years education [8]. Further, there was
differential drop out for those with more severe nico-
tine dependence as evidenced by higher baseline Fager-
ström Test for Nicotine Dependence (FTND) scores.
In more recent studies [10, 22], participants were
excluded for having a serious medical or psychiatric
disorder, other than depression.
Studies of potentially modified risk tobacco products
to date have measured a range of biomarkers, but have
tended to focus on certain reliable key measures of
nicotine exposure (e.g. cotinine), smoke exposure (e.g.
exhaled carbon monoxide [CO]), and carcinogen ex-
posure (e.g. NNAL). These markers have the advan-
tages of being well validated, are relatively specific to
tobacco smoking, and change relatively quickly in re-
sponse to changes in exposure. However, tobacco
products are a major cause of oxidative stress and
evaluation of the potential risks of different tobacco
products should include measurement of biomarkers
of oxidative stress. Tobacco smoke is an abundant
source of free radicals, containing over 1017 reactive
oxygen and nitrogen species (ROS/RNS) per puff and
considerable evidence indicates that these agents play
fundamental roles in the development of many of the
major smoking-caused diseases including cancer,
chronic obstructive pulmonary disease (COPD) and
heart disease [1]. This study will therefore include
measures of oxidative stress at baseline and during the
randomized portion of our proposed trial. We believe
this will be the first time that valid biomarkers of
oxidative stress will be assessed in a randomized trial
of RNC cigarettes.
Aim
The specific aims are to assess the effect of switching to
gradually reduced nicotine content cigarettes on:
1. Product use patterns and biomarkers of exposure in
smokers with unipolar mood and/or anxiety
disorders
We will assess biomarkers of exposure including blood
cotinine (primary measure), exhaled CO, and urinary total
NNAL and 1-hydroxypyrene. In addition, oxidative stress
biomarkers will be measured including 8-isoprostanes.
We hypothesize that smokers assigned to the RNC group
will have lower plasma cotinine concentrations during the
last 6 weeks of the randomized phase of the study than
those assigned to the usual nicotine content (UNC) group.
We further hypothesize that there will be no significant
increase in cigarette consumption, nicotine-independent
biomarkers of tobacco use (e.g., 1-hydroxypyrene, exhaled
CO), or adverse health effects (e.g., high blood pressure,
adverse respiratory symptoms) in those assigned to the
RNC group vs. those assigned to the UNC group.
2. Psychiatric and nicotine withdrawal symptoms in
smokers with unipolar mood and/or anxiety
disorders
We will measure psychiatric and nicotine withdrawal
symptoms using the Quick Inventory of Depressive
Symptomatology (QIDS) [23], Overall Anxiety Severity
and Impairment Scale (OASIS) [24], Minnesota Nicotine
Withdrawal Scale (MNWS) [25], and other measures of
stress/mental health. We hypothesize there will be no
significant increase in ratings of psychiatric or nicotine
withdrawal symptoms in those assigned to the RNC
group as compared to those assigned to the UNC.
3. Self-perception of tobacco dependence, self-report of
intention to quit smoking, and actual smoking cessa-
tion attempts
We hypothesize that smokers assigned to the RNC
group will have lower perceived dependence, be more
likely to report intention to quit smoking in the next six
months, and be more likely to make a smoking cessation
attempt during the study.
Methods/Design
This is a two-site, two-arm, double-blind, parallel group,
randomized controlled trial that will proceed in four
phases over 34 weeks. The two study sites are Penn State
University (PSU) College of Medicine and Massachusetts
General Hospital (Mass. General). Participants and study
staff will be blind to the experimental cigarette allocation
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from the randomization visit to the last visit. Visits will
occur at consistent times during the day.
Blinding of the research cigarettes
Cigarette cartons will arrive in the Penn State Investiga-
tional Drug Service (IDS) with a packaging slip that
provides information about the cartons in the shipment
which includes the nicotine content, carton bar code
number and a batch/lot number. This information will
be carefully recorded by the Cigarette Manager into
our Cigarette Management System (CMS), removed
from the carton and replaced with a blind code num-
ber. Individual packs do not contain any identifiable
information. Each individual pack will be labeled with
the carton blind code.
Study population
Tobacco cigarette smokers with a history of unipolar
mood and/or anxiety disorders throughout the greater
Hershey, Pennsylvania and Boston, Massachusetts areas
who report no quit attempt in the past month and
no plan to quit smoking in the next 6 months will be
recruited to the trial.
Inclusion and exclusion criteria
The study inclusion criteria are as follows:
 aged 18–65
 planning to live in the local area for the next
8 months
 report smoking >4 cigarettes per day (regular
filtered cigarettes or machine-rolled cigarettes with
a filter) for at least the past 12 months
 no quit attempt in the prior month and not
planning to quit smoking in the next 6 months
 no use of varenicline, bupropion (used specifically as
a quitting aid); nicotine patch; gum; lozenge; inhaler;
or nasal spray in prior month
 meet lifetime diagnostic criteria for a current or
lifetime unipolar mood disorder (dysthymia, major
or minor depression, premenstrual dysphoric
disorder) or anxiety disorder (panic disorder,
obsessive-compulsive disorder; post-traumatic
stress disorder; mixed anxiety depressive disorder,
agoraphobia, generalized anxiety disorder, social
phobia, specific phobia) based on the Mini-
International Neuropsychiatric Interview,
MINI [26]
 ability to read and write in English, comprehend and
consent to study procedures is required
The study exclusion criteria are listed below:
 pregnant and/or nursing
 any unstable or significant medical conditions such
as elevated blood pressure (systolic >160 mmHg at
baseline), recent heart attack or some other heart
condition, stroke, or severe angina, COPD requiring
oxygen, use of oral prednisone, kidney (e.g., dialysis)
or liver diseases (e.g., cirrhosis)
 any medical disorder/medication that may affect
participant safety or biomarker data
 use of any non-cigarette nicotine delivery product
(e.g., cigar, pipe, chew, snus, dip, hookah, electronic
cigarette, strips, sticks) in the past 7 days
 other serious mental illness (e.g., schizophrenia,
bipolar disorder, current eating disorder, and
dementia) or any inpatient psychiatric or substance
abuse treatment in the past 6 months
 current suicide risk on clinical assessment (above
“low risk” score on MINI [26] diagnostic interview)
 weekly use in the past 3 months of illegal drugs or
prescription drugs that are not being used for
medically prescribed purposes
 alcohol use that would hinder the participant’s
ability to participate
 a history of difficulty providing or unwilling to
provide blood samples (e.g., fainting, poor veins)
 surgery requiring general anesthesia in the past
6 weeks
 unwilling to remain on one flavor of research
cigarette (regular or menthol) for the duration of
the trial or smokes hand-rolled cigarettes
 another member of household participated or
currently participating in the study
 prisoners (at the time of enrollment)
 any other condition or situation that would, in the
investigator’s opinion, make it unlikely that the
participant could comply with the study protocol
Early withdrawal of subjects
This study is designed to identify participants who are
not able or unwilling to comply with the full study
protocol during two baseline phases (I and II) prior to
randomization. During Baseline I, participants will
smoke their usual brand of cigarettes for one week. At
Baseline II, all participants will be asked to smoke
Spectrum research cigarettes [27] with a usual nico-
tine content (about 11.6 mg) for two weeks. Partici-
pants who are removed prior to randomization will be
replaced until a total of 200 participants have been
randomized.
Recruitment, consent process and documentation
Participants will be recruited at both sites throughout
the Hershey and Boston areas by using media advertise-
ments (newspaper, radio, internet); study posters and
flyers placed on community message boards, in local
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businesses, and in clinics; community newsletters, social
media sites (e.g., Facebook) and internet websites (e.g.,
Craigslist). Interested volunteers who call the study
center number will first complete basic eligibility ques-
tions over the phone. After meeting eligibility criteria
over the phone, participants will be scheduled to come
into the study center where they will be consented to the
study and further screened and assessed for eligibility.
Procedures
Phase I: use of usual cigarette brand (baseline i – one week)
During Visit 1 screening (in-person), informed consent
will be obtained from the participant by study staff and
the usual discussion of procedure, risks, side effects,
confidentiality, voluntary participation, and right to re-
fuse participation without prejudice will be explained to
the participant. Participants must be capable of under-
standing the nature of this study, its potential risks,
discomforts and benefits before signing consent. After
consent is obtained, study staff will administer the MINI
[26], screen for drug abuse, obtain medical and con-
comitant medication histories, and measure vital signs
(e.g., blood pressure and heart rate), with eligibility
determined based on inclusion/exclusion criteria previ-
ously mentioned. For women of child bearing status, a
urine sample will be collected and eligibility screening
will include a pregnancy test.
Once a participant has been determined to be eligible,
biomeasures will be obtained; specifically, exhaled CO,
lung function (spirometry), height, weight, and waist and
hip circumferences. Participants will be asked to complete
questionnaires (see Table 1) and study staff will review the
study guidelines and provide participants with instructions
on how to keep track of the number of their usual brand
cigarettes smoked each day for one week by using a
cigarette log. All participants will be asked to refrain from
using other tobacco products or illegal drugs for the
remainder of the study, but are encouraged to report the
use of these products to the study staff.
During Visit 2, participants will be asked for their
cigarette log from the prior week and to complete ques-
tionnaires. Biomeasures similar to Visit 1 will be obtained
except, height, waist, and hip measurements. Blood (about
2 teaspoons) and urine samples will be collected at this
and future visits (except 3 & 12) for analysis. Participants
will be given Spectrum research cigarettes containing a
normal amount of nicotine (11.6 mg) matching the flavor
(regular or menthol) of their usual brand of cigarettes for
one week. The number of research cigarettes provided will
be 150% of baseline cigarettes per day and may be in-
creased throughout the study according to recent con-
sumption in order to reduce the chance of running out.
Participants will be asked to return all opened, unopened
and empty cigarette packs to the study center at each visit.
Participants who are accurate with returning their
cigarette packs and attend all study visits will be eligible
for additional compliance payments at the end of the
study.
Phase II: use of normal nicotine content research cigarettes
(baseline ii – 2 weeks)
At Visit 3 (Baseline II), biomeasures similar to Visit 2
will be obtained except for lung function (spirometry)
and no blood or urine will be collected. Participants will
be asked to complete questionnaires and will be asked
for their cigarette log from the prior week. All partici-
pants will continue to smoke Spectrum research ciga-
rettes containing a normal amount of nicotine (11.6 mg)
for an additional 1 week.
Visit 4 will be similar to Visit 2 with the same bio-
measures, completion of questionnaires, and collec-
tion of cigarette logs; however the participants who
complete Baseline II and agree to continue will enter
the Randomization Phase. They will be randomized to
either (1) continue to smoke the same 11.6 mg nicotine
Spectrum research cigarettes they smoked in Baseline II
for 18 additional weeks (UNC) or (2) switch to progres-
sively reduced nicotine content (RNC) cigarettes over
18 weeks (see Table 2). Participants will receive a 3-week
supply of research cigarettes at 150% of baseline daily
consumption to last until their next visit. There will be no
adjustments outside of the dosing schedule. Participants
in the control group will receive the same research ciga-
rettes with the same nicotine content throughout the trial.
Phase III: use of randomly assigned nicotine content
cigarettes (18 weeks)
During Phase III (Randomization), participants will have
weekly contact with the study center staff, including a
visit every three weeks. One week after an in-person
study visit, participants will complete surveys either over
the phone or by clicking on a secure survey link sent to
their personal email account. Two weeks following the
in-person visit (one week after email survey/phone con-
tact) the study center staff will contact participants to
check on progress and ask questions about the cigarettes
being smoked. Three weeks following the in-person visit,
participants will visit the study center to complete ques-
tionnaires, and return all open, unopened and empty
cigarette packs at each visit during this Phase. They will
be given another 3-week supply of research cigarettes
and biomeasures will be collected through Visit 11 as
listed in Table 1.
During Visit 10, the last visit of the Randomization
Phase, participants will be given the choice on how they
would like to complete the rest of the study and will be
encouraged to quit smoking. All participants will receive a
copy of the U.S. Surgeon General Report, “How Tobacco
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Table 1 Time and events schedule with measures, questionnaires, and procedures for study
Baseline Randomization Treatment Choice
Baseline I Baseline II Step 1 Step 2 Step 3 Step 4 Step 5
Study Week Number 0 1 2 3 6 9 12 15 18 21 25 33
Study Day 1 8 15 22 43 64 85 106 127 148 176 232
Study Visit Number 1 2 3 4 5 6 7 8 9 10 11 12
Measures/Questionnaires
Tobacco and marijuana use and daily cigarette loga X X X X X X X X X X X
Concomitant medicationsa X X X X X X X X X X X
Adverse eventsa [39] X X X X X X X X X X X
Demographics X
Tobacco use history, cigarette detailsa X X
NIDA drug use (past 3 mo) [40] X X X
Environmental smoke questionnaire [41] X X X X X X X X X X
Perceived Health Risk X X X X
Cigarette Liking Scale [42] X X X X X X X X X X
Nicotine dependence (HONC, FTND, PSU) [43–45] X X X X X X X X X X X X
Minnesota Nicotine Withdrawal Scale [25] X X X X X X X X X X X X
Smoking urges [46, 47] X X X X X X X X X X X
Audit-C [48, 49] X X X X X
Anxiety symptoms questionnaire (ASQ) [50, 51] X X X X X
CES-D[52] X X X X X
Kessler K6 scale [53, 54] X X X X X X X X X X X
OASIS (anxiety) [24] X X X X X X X X X X X
QIDS (depression) [23] X X X X X X X X X X X
Perceived Stress Scale [55] X X X X X X X X X X X
Clinical COPD questionnaire [56] X X X X X X X X X X
Menthol [57] X X X X X X X X X X
Pittsburgh Sleep Symptom and Dreams
Questionnaires [58, 59]
X X
INTERHEART and WI-PREPARE [60, 61] X X
Smoking cessation (if chosen by participant) [29] X X X
NRT disbursement (if chosen by participant) X X
Biomeasures/Proceduresb
Weight [62] X X X X X X X X X X X X
Height [62] X
Waist hip ratio [62] X X
Exhaled CO [63] X X X X X X X X X X X X
Blood pressure/pulse [39, 64] X X X X X X X X X X X X
Pulmonary function (spirometry) [65] X X X X X X X X
Urine collection X X X X X X X X X
Pregnancy test X X X X X X X
Blood collection for biomarker analysis X X X X X X X X X
Payment $40 $80 $40 $80 $80 $80 $80 $80 $80 $80 $80 $40+ compliance
NIDA National Institute on Drug Abuse, HONC Hooked on Nicotine Checklist, FTND Fagerstrom Test for Nicotine Dependence, PSU Pennsylvania State University,
ASQ Anxiety Screening Questionnaire, CES-D Center for Epidemiologic Studies Depression Scale, OASIS Overall Anxiety Severity and Impairment Scale, QIDS Quick
Inventory of Depressive Symptomatology, COPD chronic obstructive pulmonary disease, WI-PREPARE Wisconsin Predicting Patient’s Relapse, NRT nicotine
replacement therapy
aTo be completed by the researcher. All others will be completed by the participant
bAll biomeasures/procedures to be completed by researcher. Some biomarkers will be analyzed in selected subgroups of collected samples
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Causes Disease” [28] and resources available in the com-
munity to help smokers quit. Choices that will be provided
to the participant will include:
1. Return to their usual brand of cigarettes for
12 weeks (purchased at their own cost).
2. Continue to receive the research cigarettes for
12 weeks (provided at no cost).
3. Quit smoking with brief counseling from the study
team and the option to use oral nicotine
replacement therapy (NRT [gum or lozenge]) for
11 weeks.
If participants choose to return to their usual brand of
cigarettes, they will not be given any more research ciga-
rettes and will be removed from the CMS, given
cigarette pack paper logs and instructed to bring all logs
back to the next study visit 4 weeks later. If participants
choose to continue on research cigarettes, they will be
given a 4-week supply of either UNC or RNC research
cigarettes (150% of baseline cigarettes per day) corre-
sponding to the cigarettes they were given at the last
visit of the participant’s treatment group allocation,
given cigarette pack paper logs and instructed to bring
all logs and research cigarette packs back to the next
study visit 4 weeks later. If participants choose to quit
smoking, they will be given up to a 6-day supply of
research cigarettes corresponding to the cigarettes they
were given at the last visit of the participant’s treatment
group allocation. These cigarettes are intended to last
until their target quit date. Participants who choose to
quit will also be given cigarette pack paper logs and
instructed to bring all logs and research cigarette packs
back to the study center one week later for their in-
person counseling session. Regardless of the participant’s
choice, all participants will attend two additional follow
up visits four weeks (visit 11) and 12 weeks (visit 12)
after the end of the randomized phase.
Phase IV: treatment choice (12 weeks)
Quit arm Participants who choose to quit smoking
must be willing to set a quit date within the following
week and will be offered a flexible smoking cessation
treatment. They will have the option to receive up to
11 weeks of short-acting NRT (gum or lozenges) at no
cost and cognitive behavioral-based smoking cessation
counseling provided by study staff, in-person or over the
phone. In addition to regular study visits (week 25 [Visit
11] and week 34 [Visit 12]), there will be two optional
additional in-person sessions (weeks 23 and 30), four
phone sessions (weeks 23, 24, 28, and 32) and five self-
guided sessions. In order to avoid missed phone sessions,
researcher and participant will attempt to agree on a
standing appointment, day and time. Participants will re-
ceive 20 min (or less) of standard individual cognitive
behavioral therapy (CBT) based on the Freedom from
Smoking (FFS) curriculum (http://www.ffsonline.org/)
from the American Lung Association. They will be given
strategies to cope with triggers/urges to quit.
During the first in-person quit visit (week 22), one day
after the participant’s target quit date, exhaled CO will
be measured, adverse events and concomitant medica-
tions will be assessed and participants will complete
questionnaires. Participants will return all cigarette packs
(6-day supply), bring completed cigarette logs, and be
evaluated by study staff for nicotine withdrawal symptoms
and be removed from the CMS. If the participant chooses
Table 2 Nicotine content dosing schedule for study
Phase Baseline I Baseline II Randomized Double-Blind Phase Treatment
Choice Phase





















600 500 400 300 200 102
Spectrum
Code: menthol
601 501 401 301 201 103
Approximate nicotine content in mgs per cigarette (mg/gram)a
RNC Around 13 mgb 11.6 7.4 3.3 1.4 0.7 0.2 Variable
(19) 16.5 (10.6) (4.7) (1.9) (0.9) (0.3)
UNC Around 13 mgb 11.6 11.6 11.6 11.6 11.6 11.6 Variable
(19) (16.5) (16.5) (16.5) (16.5) (16.5) (16.5)
aThese are averages of menthol/non-menthol cigarettes at each level based on estimated 0.7 g tobacco content per cigarette and nicotine concentrations based
on Richter et al. [27]
bEstimated mean nicotine content and concentration based on Connolly et al. [66]
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to use NRT they will receive 3 boxes of either nicotine
gum (110 pieces/box) or lozenges (81 pieces/box) ac-
cording to the participant’s preference. Adverse events
and concomitant medications will be assessed and a
questionnaire (Smoking Cessation Quit Day) [29] that
includes the MNWS [25]. By this visit, some partici-
pants will have transitioned to smoking very low nico-
tine content research cigarettes. Decisions about dosing
will be determined based on participant reported with-
drawal symptoms. Participants who may have tapered
to very low nicotine cigarettes should have minimal
withdrawal symptoms and may require very low NRT
dosing. A general guideline for NRT dosing will be used
to make recommendations to participants as follows:
Group 1:
 Not able to remain abstinent or
 Reports a score of 2 or more on the MNWS items
#1 and #4 (irritable/angry and/or craving to smoke)
Group 2:
 Able to remain abstinent and
 Reported a score of 0 or 1 on MNWS items #1
and #4 or
 Had few slips
The day after the week 22 visit, a researcher will call
the participant to assess whether the participant is
experiencing any side effects from the NRT. Additional
courses of NRT will be given to the participant, as
needed, either at study visits, or if the participant calls in
to the study center to request additional NRT.
At Visits 11 and 12 (Treatment Choice), all partici-
pants will complete questionnaires and study procedures
as done in previous visits, except no blood or urine will
be collected at Visit 12. At Visit 11, if participants chose
to receive research cigarettes, they will be given an add-
itional 8-week supply of either UNC or RNC research
cigarettes (150% of baseline cigarettes per day) corre-
sponding to the cigarettes they were given in the last
visit of the participant’s treatment group allocation.
Participants who chose to use NRT to quit smoking,
could be given a refill of oral NRT (3 boxes of gum or
lozenge) as appropriate depending on the participant’s
NRT usage and withdrawal symptoms. For participants
who chose to quit smoking, the NRT dosing schedule
will be discussed at weeks 26 and 30.
At Visit 12, no further counseling, NRT or study ciga-
rettes will be given to the participants. The study
cigarette log will be reviewed and the total number of
cigarettes smoked will be recorded. Each participant will
be assessed for eligibility for the final study incentive
payments for (a) study visit compliance ($50) and (b)
cigarette pack return accuracy ($50). Participants will be
eligible for study visit compliance if they attended all
study visits and provide data. Participants will be eligible
for the cigarette pack return accuracy compliance incen-
tive if they returned all research packs (opened and un-
opened) within a margin of 4 packs for 6 out of 8 study
visits where research cigarette return was required
(Visits 3, 4, 5, 6, 7, 8, 9, and 10).
The sequence for all study visits, from screening to
follow-up are shown in Fig. 1.
Primary outcome
The primary outcome variable is plasma cotinine con-
centration (measured as ng/ml) during the last 6 weeks
of the randomized phase. The mean value of this con-
tinuous measurement will be compared between two
groups: the experimental group (RNC cigarettes) and
the control group (UNC cigarettes).
Secondary outcomes
The secondary outcome measures include exhaled CO
and urinary total NNAL and 1-hydroxypyrene, cigarette
consumption, and health effects (e.g., blood pressure,
respiratory symptoms). In addition, oxidative stress bio-
markers including 8-isoprostanes will be measured.
Some biomarkers will be analyzed in selected subgroups
of collected samples.
The proportion of each group making a choice to try
to quit smoking will be an endpoint, as will the propor-
tion succeeding in quitting successfully during the
choice phase. Intent to treat (ITT) abstinence (based on
the assumption that a loss-to-follow-up subject resumes
smoking) and completers’ abstinence (based on the
assumption that the probability of loss to follow up is
independent of smoking status) will be analyzed. Abstin-
ence will be biochemically verified (CO ≤9 ppm).
Sample size
For plausible effect size and variation, we used results of
Benowitz et al. [8], where the mean and standard devi-
ation of plasma cotinine concentration are 240 and 120
for the control group and 113 and 116 for the experi-
mental group at the 22nd week follow-up visit (end of
randomization phase for trial). It is expected that the
cotinine level in the experimental group will reduce
gradually after start of the trial and the mean difference
of the cotinine level between these two groups for our
study will be smaller than the difference of 127 ng/ml in
Benowitz et al. [8]. With a sample size of 70 participants
per group, we are able to detect the difference in plasma
cotinine concentration level between the two groups as
small as 58 ng/ml (which could occur on the 7.4 mg
nicotine content cigarettes) with at least 80% power (and
68 ng/ml with at least 90% power). Allowing for a 30%
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participant –withdraw rate, we plan to recruit 100 par-
ticipants for each group (a total of 200). The alpha level
used for the power analysis is 0.05.
Additional statistical power analyses will be performed
based on secondary aims: to examine the difference in
biomarkers of tobacco smoke exposure, nicotine with-
drawal, and psychiatric symptomatology, with a sample
size of 70 subject completers per group, we are powered
to detect an effect size of 0.5 (difference is half of the
standard deviation) between the two groups with at least
83% power. Also, with a completing sample size of 70
per group we are able to detect a 15-20% difference in
the proportion of subjects willing to quit between these
two groups (depending on the proportion in the control
group) with about 80% power. If the proportion differ-
ence was as large as the value in the Benowitz et al. [8]
study (51% of the RNC group versus 14% of the control
group) then our statistical power will be as high as
99.8%. It was assumed that both groups have equal
drop-out rate (30%) when the sample size was calculated
Fig. 1 Study design timeline for the two-site, two-arm, 34-week, double-blind, parallel group, RCT in four phases
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above. However, it is possible that we could have differ-
ential dropout rate in the two groups. Benowitz, et al.
[8] had 9% dropout in the control group versus 33% in
the intervention group. We have 99% statistical power in
detecting a difference as large as this (9% vs. 33% for
dropouts).
Withdrawal criteria
Participants will be withdrawn from the study any time
prior to randomization if:
1. They report using non-cigarette nicotine products
at more than one visit. This includes any number
of cigars, pipes, snuff, chew, hookah, electronic
cigarette, marijuana, or any other illegal smoked
substance.
2. They are not able to attend a study visit within the
allowed visit windows (i.e., participant misses a
scheduled study visit AND any subsequent make-up
visit that is arranged).
During Baseline II only, participants will be withdrawn
from the study if:
1. Participant’s total cigarette consumption includes
more than 10% of non-research cigarettes in the
6 days prior to visit 4 only (average cigarettes
from day 15–20, e.g., 4 or more out of 30
cigarettes in 6 days for a 5 cigarette per day
(CPD) smoker; 18 or more out of 180 cigarettes
in 6 days for a 30 CPD smoker).
2. Participant has reduced their cigarette consumption
by more than 50% from baseline (when CPD are
averaged over days 15–20).
3. Significant baseline smoking rate increase: A
participant will be withdrawn from the study if they
meet BOTH of the following criteria:
a. The average CPD increase by more than 100%
from the average CPD at the Baseline II
assessment (visit 4) when calculated over the
previous 6 days.
b. The average of two consecutive expired breath
carbon monoxide (CO) measurements increase
according to the following:
i. CO is greater than 50 ppm if CO at
assessment visit 1 is <20 ppm.
ii. CO is greater than 60 ppm if CO at
assessment visit 1 is 20–34 ppm.
iii. CO is greater than 70 ppm if CO at
assessment visit 1 is 35–49 ppm.
iv. CO is greater than 80 ppm if CO at
assessment visit 1 is 50–60 ppm.
v. CO is greater than 90 ppm if CO at
assessment visit 1 is 61–70 ppm.
Participants may be discontinued by the investigator at
any point during the study for any reason that meets the
inclusion, exclusion, or early withdrawal criteria. If
participants are withdrawn from the study for any
reasons noted above during Baseline I or II (prior to
randomization), they will be replaced until a total of 200
participants have been randomized to the study. Par-
ticipants who voluntarily withdraw from the study
will be asked to complete a questionnaire regarding
the reasons for dropping out and what they didn’t/did
like about the study.
Data management and monitoring
Participants will be under medical supervision while in
the study and seen on an ongoing basis by our study staff
who will assess adverse events and make appropriate re-
ferrals to the physician. The Data Safety Monitoring Board
(DSMB) will oversee the safety of the participants in the
trial. The DSMB will receive summary reports on recruit-
ment, retention, adverse events (AEs), and CO and
produce a report and recommendation annually.
Statistical analysis
Study data will be collected and managed using RED-
Cap electronic data capture tools hosted at the Penn
State Milton S. Hershey Medical Center and College of
Medicine. REDCap is a secure, web-based application
designed to support data capture for research studies
[30]. Statistical analysis and additional data manage-
ment will be performed using R 3.3 (R foundation,
https://www.r-project.org/). Complete summary statis-
tics will be provided for all variables at baseline and
across the trial period, separately for the two trial arms
where appropriate. Graphs such as Boxplots and longitu-
dinal trajectory plots will be used to visualize the data.
Outliers and questionable data points will be investigated
for quality assurance. The demographic characteristics,
smoking history and other baseline measures will be com-
pared between the two arms to validate the effectiveness
of the randomization procedure.
The statistical analysis will focus on comparing the
two trial arms (reduced nicotine content vs. usual nico-
tine content cigarettes) on the following endpoints: (a)
cotinine concentrations during the last 6 weeks of the
randomized phase; (b) change of QIDS depression level
and OASIS anxiety measure from baseline to last 6 weeks
of randomized phase; (c) dropout rate from the trial by
the end of the randomized phase; (d) rate of psychiatric
serious AEs and (e) the proportion of subjects that try to
quit smoking at the end of the randomized phase. For
endpoints (a) and (b), mixed effects regression models
will be used to model their change over the trial period
and the difference of the trajectories between the two
arms. For endpoints (c), (d) and (e), logistic regression
Allen et al. BMC Public Health  (2017) 17:100 Page 10 of 13
and Poisson regression will be used. Other endpoints
such as smoking behaviors will also be compared but on
an exploratory basis.
Compliance, along with dropouts, will be treated as an
additional outcome measure. We will conduct a separate
statistical analysis for the subgroup of participants who
are judged to be completely compliant. Non-compliance
will be described as a continuous as well as a categorical
measure (greater than 10% of cigarettes smoked were
non-study cigarettes). We will also examine the extent
of use of pharmaceutical products or other alternative
tobacco products during the 18 week randomized study
period. In our analysis, we will add both dropouts and
compliance as an outcome variable.
Discussion
Among nicotine dependent smokers, 22% have a mood
disorder and 23% have an anxiety disorder (compared
with 7% and 10% of nonsmokers) [31]. Smokers with a
comorbid psychiatric illness may be more vulnerable to
unintended effects of a progressive nicotine reduction
policy at the national level. These smokers, by the nature
of their comorbid psychiatric illness, may experience
chronic high levels of psychological distress, may be
more sensitive to nicotine withdrawal symptoms, and
may be more likely to exhibit compensatory smoking
behavior in order to maintain systemic nicotine concen-
trations. Smokers with mental illnesses report wanting
to quit smoking, trying to quit smoking, and use of
smoking cessation aids at similar rates to people without
mental health problems, but have higher levels of nico-
tine dependence and may be less likely to succeed when
they attempt to quit smoking than smokers without a
comorbid psychiatric illness [32, 33].
The reasons for the high comorbidity between mood
and anxiety disorders and nicotine dependence are not
fully understood. Many studies have found that smokers
with affective disorders report elevated nicotine with-
drawal symptoms during early abstinence, compared to
those without [15, 34–36]. Potential mechanisms have
been identified. For example, smokers with a prior major
depressive episode have greater smoking-induced brain
dopamine release than those without such a history [37].
Monoamine oxidase A (MAO-A), an enzyme that metab-
olizes monoamines, including dopamine, and, through this
mechanism, modulates mood, is increased in the brains of
heavy smokers during abstinence. This effect, which
covaries with severity of depression, suggests one possible
biological mechanism for depressive symptoms as part of
the nicotine withdrawal syndrome [38].
For the reasons described above, smokers with mood
and anxiety disorders may be particularly vulnerable to
unintended effects of a policy of progressive nicotine
reduction in cigarettes. It is not known if smokers with
these conditions are more likely to “oversmoke” reduced
nicotine cigarettes and experience increased toxin ex-
posure as a result. It is also possible that smokers with
mood and anxiety disorders may experience some ex-
acerbation in their psychiatric symptoms as they grad-
ually withdraw from nicotine under a nicotine reduction
policy. On the other hand, if smokers with mood and
anxiety disorders can safely transition to significantly
reduced nicotine content cigarettes, it is plausible that
further progression to smoking cessation may be more
achievable from a lower level of nicotine dependence.
We therefore propose to examine the effects of
switching to reduced nicotine content cigarettes in
smokers with current anxiety and mood disorders. We
see this as a critical test of the feasibility of the RNC
regulatory strategy.
Results from this study will inform on effects of regu-
lating nicotine content of cigarettes and help determine
whether smokers with mood and anxiety disorders can
safely transition to significantly reduced nicotine content
cigarettes and further progress to smoking cessation.
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